ANAPTYSBIO, INC. Derivative Liability, Noncurrent
ANAPTYSBIO, INC. (ANAB) had Derivative Liability, Noncurrent of $0 as of 2017-12-31, per its 10-K filed 2018-03-05.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2018-03-05
- 2017-12-31: Derivative Liability, Noncurrent $0.00.
- 2017-09-30: Derivative Liability, Noncurrent $0.00.
- 2017-06-30: Derivative Liability, Noncurrent $0.00.
- 2017-03-31: Derivative Liability, Noncurrent $0.00.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-05 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-07 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-10 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-12 |
| 2016-12-31 | $3.24M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |